Allogene Files Form 144 to Sell 4,835 Shares

Allogene Therapeutics filed a Form 144 reporting a proposed sale of 4,835 shares of Common Stock listed on NASDAQ.

Rhea-AI Filing Summary

Allogene Therapeutics filed a Form 144 reporting a proposed sale of 4,835 shares of Common Stock listed on NASDAQ. The filing shows a related vesting of a restricted stock unit award on 03/13/2026 granted under the issuer's equity compensation plan. The Form 144 entry is dated 03/16/2026.

Insights

Equity Compensation Analyst

Form 144 notifies a proposed sale of vested compensation shares.

The filing lists 4,835 shares of Common Stock tied to a restricted stock unit vesting on 03/13/2026 under the issuer's equity compensation plan. The notice was recorded on 03/16/2026 and references NASDAQ.

Cash‑flow treatment and price details are not shown in the excerpt; subsequent filings or broker reports would disclose execution details if and when the sale occurs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Allogene's Form 144 filed on 03/16/2026 report?

The filing reports a proposed sale of 4,835 shares of Common Stock on 03/16/2026. It also notes vesting of a restricted stock unit award on 03/13/2026 under the issuer's equity compensation plan.

Do the Form 144 details show proceeds or sale price for ALLO shares?

No, the provided excerpt does not state the sale price or proceeds. The Form 144 lists share quantity (4,835) and dates; execution price and proceeds would appear in subsequent trade reports or broker disclosures.

Is the proposed sale tied to equity compensation at Allogene (ALLO)?

Yes. The filing explicitly links the securities to the vesting of a restricted stock unit award on 03/13/2026, noting the award was granted under the issuer's equity compensation plan.

Which exchange and date are shown in the Form 144 excerpt for ALLO?

The excerpt references NASDAQ for the Common Stock and shows the Form 144 entry dated 03/16/2026. The related RSU vesting date shown is 03/13/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 08:20 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002057918
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Allogene Therapeutics, Inc.
SEC File Number	001-38693
Address of Issuer	210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	(650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold	Beneski Benjamin Machinas
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4835	11927.50	243777920	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/13/2026	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.			4835	03/13/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	03/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	BENJAMIN MACHINAS BENESKI
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)